Plant Health Care – recommended offer, “attractive value” for shareholders?

Plant Health Care (PHC) is “pleased to announce” the terms of a recommended offer for the company, emphasising “a significant premium to the current share price and allows shareholders to realise immediate and attractive value for their shareholding… PI has the heft, the capability and the determination to underpin the next phase of growth of Plant Health Care's exciting journey”. What about this and a current around 8.7p share price?

Plant Health Care – “Expanded New California Label for Employ”, but reducing balance sheet strength?

Describing itself as “a leading provider of peptides used by growers to improve crop production and quality within global agriculture markets”, Plant Health Care (PHC) has announced that The California Department of Pesticide Regulation has approved a range of new crops for the company’s Employ (Harpinαβ) product. What about a current approaching 10% higher share price response towards 7p?

Plant Health Care – argues “strong” trading, sufficiently strong for a more than 25% share price increase response?

Describing itself as “a leading provider of peptides for plant protection to global agriculture markets”, Plant Health Care (PHC) has issued a trading update including emphasising “in the US, on-ground sales have started the year strongly… Outside the US, sales by PHC grew strongly in 2023 and have continued that trend in the first four months of 2024”. Just how ‘strong’ is that trading though, with the shares currently up more than 25% at 4.345p?

Plant Health Care – “Brazil approves TEIKKO… excited about the developing plans”. Er, what about the developing funding situation?

Describing itself as “a leading provider of peptides used by growers to improve crop production and quality within global agriculture markets”, Plant Health Care (PHC) “is pleased to announce that its nematicide, TEIKKO, has received federal approval in Brazil in time for commercial launch for the 2024/25 soybean growing season”. What of this and a share price response up to 3.815p?

Plant Health Care – trading warning, though argues ‘well positioned’ for growth in 2024 and beyond. How ‘well’ really though?…

Plant Health Care (PHC) has issued a “trading update” including that, with “challenging market conditions, particularly in the key USA end market, the company now anticipates revenue in FY2023 to be in line with or show modest growth over the year ended 31 December 2022”, though that it “continues to make significant progress in obtaining new product registrations and widening geographic distribution, positioning the company well for growth in 2024 and beyond”. So what of a current around 4p share price, down more than 30%?

Plant Health Care (#PHC) – biochemical fungicide PHC279 for sugar cane and coffee federal approval in Brazil

Plant Health Care (#PHC) – raises £2.8m at 9p per share

Plant Health Care – “remains committed to its listing on AIM, including for any potential funding needs”. Such ‘needs’ soon?...

Agriculture plant protection company Plant Health Care (PHC) has announced that from a consultation process it is “clear… that investors are consistently supportive of the company's track record of delivering growth over recent years… there is clearly a prevailing view that the company should remain listed”. With this following a previous announcement that the company was to consult as to whether AIM remains the right environment for it, the shares have currently responded approaching 9% higher to above 11p. So what now?

Plant Health Care (#PHC) – following shareholder consultation, to continue with AIM listing

Plant Health Care – 2022 results, is “frustrated” by the share price performance justified?

Provider of biological products to enhance farming, Plant Health Care (PHC) states that it “is pleased to announce its results for the year ended 31 December 2022… revenue up 40% to $11.8m… on track to deliver long-term targeted revenue, cash breakeven and profitability”. So what of a current share price of 9.5p, down 18%, despite the announcement including that already “the board is frustrated that the company's share price performance does not reflect the positive progress in the delivery of its strategy”?

Plant Health Care – peptide fungicide US approval, a “significant milestone”?

Plant Health Care (PHC) “is pleased to announce US Environmental Protection Agency commercial approval of its novel peptide fungicide, coded as PHC279” and that “Wilbur-Ellis Agribusiness, one of the largest U.S. retailers of agricultural products, is expected to commence sales of PHC279 within key US markets under the brand Obrona in 2023”. So what of a current more than 8.5% higher share price response to 11.4p?

Plant Health Care – argues revenue growth “strong performance”, BUT...

Plant Health Care (PHC) has updated emphasising “the company's revenue growth in the first half of 2020 is a strong performance, which demonstrates the merits of exposure to agriculture, as an essential industry” and “Covid-19 has had limited impact on the business to date”. The shares though are currently still at 9.625p, down from 15p+ in February...

Plant Health Care (#PHC) – H1 loss on revenue up to $3.1m, retains “cautious” outlook

Plant Health Care – you were warned & now “delighted to have the support of shareholders”… as seeks to deliver a smaller investor screwing!

Early this month I noted announcements from Plant Health Care (PHC) which had helped the shares to 12.5p ramptastic and concluded I’d certainly wait and see on “well positioned” – and currently continue to avoid. Now (natch) “Placing and Subscription”…

Plant Health Care (#PHC) – proposed minimum $4m placing & subscription at 8p per share, a 44% discount!

Plant Health Care – argues “significant” regulatory approval… but how ‘well positioned’?

Plant Health Care (PHC) has today followed two January announcements with another – which has currently helped the shares to 12.5p, a further approaching 9% higher…

Plant Health Care – warns & I thought it was to be “cash positive… within our existing cash reserves”?!...

Previously writing on agriculture biological products company Plant Health Care (PHC), in September it was “delighted”… but it’s an RNS Reach again & market seeing through it this time?. Now “Trading Update” – and the shares currently back at 7.5p, capitalising the company at circa £15.5 million, more than 12% lower on the day…

Plant Health Care – “delighted”… but it’s an RNS Reach again & market seeing through it this time?

Last month a “Progress with PREtec field trials in Brazil” announcement from Plant Health Care (PHC) saw the shares soar towards 9p. They had since slid back to 7.5p – and today a “Pilot production of PREtec peptides” announcement…

Plant Health Care – shares soar on ‘extremely encouraging’ field trial results… but beware, it’s an RNS Reach…

Plant Health Care (PHC) “is pleased to provide” an update on field trials of its PREtec peptide PHC279 for the control of Asian Soybean Rust in Brazil – and the shares have responded currently more than 50% higher, towards 9p…

Plant Health Care – sales warning, but still argues “very encouraged” & “confidence”. Really?

Updating last month on Plant Health Care (PHC), I concluded, with the shares at 10.1p,… “much to be achieved from the reported position - and also having noted previously what happened with some previous confidence from the company - I currently continue to avoid”. Now a near last minute before Christmas “Trading Statement”…